Enliven Therapeutics (ELVN) 2025 Conference June 04, 2025 03:45 PM ET Speaker0 It's your Speaker1 day. Just grinding through this. Speaker0 It's fine. Yeah. It's gonna run around. It's like a barn. But it's good though. All set? Yeah. Okay. Hi, everyone. My name is Maury Raycroft and one of the biotech analysts at Jefferies. I'm happy to introduce Sam Kintz, the CEO of Enliven Therapeutics. Thanks for joining us today, Sam. And we're gonna do fireside chat format. So maybe for those who are new to the story ...

Inotiv (NOTV) 2025 Conference June 04, 2025 03:45 PM ET Speaker0 Okay. Okay. Alright. Hi. Good afternoon. I'm Dave Windley with Jefferies Healthcare Equity Research, CRO coverage. Thanks so much for attending or listening to our twenty twenty five Healthcare Conference here in New York. Our next presenting company is Innative. NOTV is the ticker and the company's CEO is here with us. Bob Leisure, Beth Taylor here in front of me in the audience. The company's CFO is also along with. So Bob, we just said this ...

Scholar Rock Holding (SRRK) 2025 Conference June 04, 2025 03:45 PM ET Speaker0 Fantastic. All right. Well, thank you. Good afternoon everyone. Welcome to the next session here at the Jefferies Healthcare Conference. I'm Michael Yee, a senior biotechnology analyst, and really happy to have a couple members of the ScholarRock management team with us. And importantly, this somewhat of a new team that got introduced over the last month. So I'd love perhaps, although David, you were chairman, an opportunity for ...

Adtalem Global Education (ATGE) 2025 Conference June 04, 2025 03:45 PM ET Speaker0 All right. We're gonna get started. Good afternoon. My name is Steven Pollock, the Baird research analyst covering post secondary education here at Baird. Our next presenting company is Adtalem Global Education. They operate five healthcare focused institutions in The U. S. With more than 80,000 students currently enrolled. Here from the company, we have CEO, Steve Beard. We also have in the audience CFO, Bob Phelan and Head ...

Allurion Technologies (ALUR) 2025 Conference June 04, 2025 03:45 PM ET Speaker0 Alright. We can, we can make a start here. I'm Michael Toomey covering for for Matt Taylor, US med tech analyst at Jefferies. Pleased to be joined by Shantanu Gore, founder and CEO of Allurion. So thank you for joining us today. So maybe we can just level set to start for people not as familiar with the story. Obviously, you founded the company and just run us through maybe a history of Allurion and where we are today. Speaker1 ...

Summary of Wave Life Sciences Conference Call Company Overview - **Company**: Wave Life Sciences (WVE) - **Event**: 2025 Jefferies Global Healthcare Conference - **Date**: June 04, 2025 Key Points Industry and Pipeline - Wave Life Sciences is focused on RNA editing, aiming to establish a new category of medicine with its unique chemistry [5][6] - The company has multiple pipeline programs, with a lead program targeting alpha-one antitrypsin deficiency (ATD) [3][4] Alpha-One Antitrypsin Program - Upcoming data sets include a 200 mg cohort in Q2 and a 400 mg cohort later in the year [4][8] - Initial data showed therapeutic levels of alpha-one antitrypsin protein, with 11 micromolar total protein and 7 micromolar of the edited M protein [5][6] - The program aims to demonstrate the potential for monthly dosing based on the observed protein production [6][8] - The collaboration with GSK includes over $520 million in milestones and $2.3 billion in total milestones related to the RNA editing pipeline [18][19] Obesity Program - The obesity program (HIBE) is in Phase 1, with data expected later this year [21][22] - The study includes subtherapeutic and therapeutic cohorts, with a focus on weight loss mechanisms and safety [22][26] - Inhibin E is highlighted for its potential to drive fat loss without muscle loss, showing a favorable metabolic profile in heterozygous patients [25][26][28] DMD and Huntington's Disease Programs - For Duchenne Muscular Dystrophy (DMD), discussions with the FDA are ongoing regarding accelerated approval based on dystrophin expression and muscle health data [39][40] - The company is also preparing for a pivotal trial for Huntington's disease, utilizing natural history data to measure patient progression [42][43] Regulatory Environment - The regulatory landscape for Huntington's disease is evolving, with potential changes in endpoints that could benefit Wave Life Sciences [43][44] - The company is positioned to adapt to changes in regulatory expectations, particularly regarding mutant huntingtin as a clinical surrogate endpoint [44] Additional Insights - The focus on RNA editing and the unique delivery mechanisms may differentiate Wave Life Sciences from other companies in the siRNA space [31][32] - The potential for once or twice a year dosing in obesity treatment could significantly expand market opportunities [36][37] - The emphasis on safety, tolerability, and target engagement in clinical trials is critical for advancing the pipeline [28][30]

PAR (PAR) FY Conference June 04, 2025 03:40 PM ET Speaker0 Alright. Good afternoon. Thank you for joining for the PAR technology session. I'm Steven Sheldon. I'm an analyst in the tech group at William Blair, green vertical technology including PAR. Please visit our website at williamblair.com for a complete list of research disclosures and potential conflicts of interest. It's great to have the PAR team back at our conference again this year. A lot to dig into especially with its continued strong sales mom ...

Travere Therapeutics (TVTX) 2025 Conference June 04, 2025 03:10 PM ET Speaker0 Hello everyone. My name is Farzin Hak, one of the biotech analysts at Jefferies in Moriw Baycroft's team. I'm happy to introduce Eric Dubay, CEO of Trivia Therapeutics. This is a fireside chat format. Thank you for joining us today, Eric. Speaker1 Well Farzan and Jeffries, thanks so much for hosting us. Speaker0 So for those who are new to the story, can you provide a one minute overview of your programs and strategic focus? Spea ...

NetApp (NTAP) 2025 Conference June 04, 2025 03:10 PM ET Speaker0 Okay. Great. Can everyone hear me? Great. Hello. My name is Colin Liet. I'm on the Internet and interactive entertainment team here at Baird working on our call with Sebastian. Today, we're happy to have here with us NetApp's VP of Investor Relations, Chris Newton. And just to start us off, she's gonna have a safe harbor to read for us. Speaker1 Hey, everyone. Today's discussion may include forward looking statements regarding NetApp's future ...

Merus (MRUS) 2025 Conference June 04, 2025 03:10 PM ET Speaker0 Hi, everyone. My name is Maury Raycroft, and I'm one the biotech analysts at Jefferies. It's with great pleasure that I'd like to welcome the CEO of Meris, Bill Lundberg. Thanks so much for joining us today, Bill. And we're going to do fireside chat format. So maybe for those who are new to this story, if you can give a brief intro to to Meris. Speaker1 Sure. First and foremost, I wanted to thank you, Morin, and the entire team at Jefferies for ...